After the books closed: the quarter's biggest news happened too late to be in the numbers
The model's full reasoning — Q4 2022 call → NOThe question asks whether management reports that the most important positive developments of the period happened so late in the reported period or shortly after it ended that the results being presented contain little or none of their effect — with management itself marking the timing. Let me analyze the transcript for this specific pattern. Key events mentioned: 1. Fazirsiran (AAT) - SEQUOIA data are in, waiting for FDA feedback on Phase 3 design. Takeda submitted Phase 3 protocol at end of last quarter. They expect to report topline data and provide Phase 3 guidance together. 2. Cardiometabolic programs - interim analyses presented at AHA. 3. Pulmonary programs (ARO-RAGE, ARO-MUC5AC) - progressing, interim data expected in first half of 2023. 4. ARO-C3 - interim data expected first half of 2023. 5. New cell type announcement - first half of 2023. 6. 20 in '25 program. 7. Royalty Pharma deal - sold olpasiran royalties for $250M upfront, announced November 9, 2022 (after fiscal year end September 30, 2022). Now, the fiscal year ended September 30, 2022. The Royalty Pharma deal was announced November 9, 2022 — after the period ended. This is a concrete positive development (cash received). But does management frame this as "the results contain little or none of their effect" and treat it as "the real story the numbers missed"? Let me look at how the Royalty Pharma deal is discussed. Ken Myszkowski says: "Pro forma cash and investments at September 30, 2022 including the Royalty Pharma cash receipt would be $732.3 million." This is a pro forma adjustment, acknowledging the deal happened after period-end. Chris Anzalone mentions it in his closing remarks: "We have provided better clarity with respect to our balance sheet with our sale of olpasiran royalty rights for $250 million upfront plus $160 million in potential additional payments." But is this framed as "the most important positive development" that the numbers missed? The deal is mentioned as one of several items in a list of "clarity" items. It's not really framed as the story the numbers missed. What about the fazirsiran SEQUOIA data? The data are "mostly in now" and they're waiting for FDA feedback. This is a late-breaking development but it's not yet reported — they're waiting to communicate it.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASM | Avino Silver & Gold Mines Ltd. | Q4 2023 | 2024-03-21 | C+ |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| SWBI | Smith & Wesson Brands, Inc. | Q1 2023 | 2022-09-08 | C+ |
| YMM | Full Truck Alliance Co. Ltd. | Q2 2022 | 2022-08-25 | C+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| RNW | ReNew Energy Global Plc | Q2 2022 | 2021-11-18 | C |
| BFI | BurgerFi International, Inc. | Q3 2021 | 2021-11-12 | C |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
OPK · Q1 2022 → YESThe question is: Does management report that the MOST IMPORTANT POSITIVE DEVELOPMENTS of the period happened SO LATE IN THE REPORTED PERIOD, OR SHORTLY AFTER IT ENDED, that the results being presented...YES The transcript shows management treating the ModeX acquisition (announced and closed on the call date, May 9) and the Sema4/GeneDx deal (closed April 29) as major positive developments that occurred after the Q1 period ended. These are framed as key steps toward unlocking value and are highlighted as the "exciting announcement" that changed the call format.
RNW · Q2 2022 → YESThe question is: Does management report that the MOST IMPORTANT POSITIVE DEVELOPMENTS of the period happened SO LATE IN THE REPORTED PERIOD, OR SHORTLY AFTER IT ENDED, that the results being presented...YES The transcript shows management explicitly marking the timing of key positive developments: 400 MW commissioned "since the end of the quarter" (bringing operating capacity to 7 GW today, with another 400 MW scheduled "over the next couple of weeks"), plus the completed Telangana acquisition adding 260 MW.
ASM · Q4 2023 → YESThe question is: Does management report that the MOST IMPORTANT POSITIVE DEVELOPMENTS of the period happened SO LATE IN THE REPORTED PERIOD, OR SHORTLY AFTER IT ENDED, that the results being presented...